Royalty Pharma PLC (NASDAQ:RPRX) Stake Lessened by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lessened its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 7.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 86,918 shares of the biopharmaceutical company's stock after selling 7,290 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Royalty Pharma were worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. US Bancorp DE lifted its holdings in Royalty Pharma by 151.3% in the fourth quarter. US Bancorp DE now owns 9,565 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 5,759 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Royalty Pharma by 806.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,431 shares of the biopharmaceutical company's stock valued at $113,000 after buying an additional 3,942 shares in the last quarter. State of Michigan Retirement System lifted its stake in shares of Royalty Pharma by 16.2% in the 4th quarter. State of Michigan Retirement System now owns 19,400 shares of the biopharmaceutical company's stock valued at $495,000 after purchasing an additional 2,700 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Royalty Pharma by 4.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock valued at $79,888,000 after purchasing an additional 130,025 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Royalty Pharma by 15.2% during the 4th quarter. Victory Capital Management Inc. now owns 978,211 shares of the biopharmaceutical company's stock worth $24,954,000 after acquiring an additional 129,176 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Trading Down 0.8%

Shares of NASDAQ:RPRX traded down $0.28 during midday trading on Friday, reaching $35.84. The company's stock had a trading volume of 1,690,401 shares, compared to its average volume of 3,702,663. The firm has a market cap of $20.15 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.85 and a beta of 0.50. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.68. Royalty Pharma PLC has a 1 year low of $24.05 and a 1 year high of $36.56. The business has a 50 day moving average price of $34.19 and a 200 day moving average price of $32.31.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. The firm had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Research analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.46%. The ex-dividend date was Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is 47.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Morgan Stanley set a $54.00 price target on Royalty Pharma and gave the company an "overweight" rating in a research report on Thursday. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Finally, Wall Street Zen cut Royalty Pharma from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Royalty Pharma currently has a consensus rating of "Buy" and a consensus price target of $48.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.